TMCnet News
Enbrel Biosimilars Clinical Trial & Opportunity Insights 2016 - Research and MarketsResearch and Markets has announced the addition of the "Enbrel Biosimilars Clinical Trial & Opportunity Insight" report to their offering. The Enbrel Biosimilars Clinical Trial Insight report gives comprehensive clinical insight on 36 biosimilar versions of Enbrel drugs in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials and are expected to be commercially available in the next 5-8 years. Currently 5 biosimilar versions of Enbrel are commercially available in Iran, Mexico, India, UK and Australia. The patent on Enbrel was originally set to expire on October 23, 2012, but in the United States, a second patent, granting exclusivity for another 16 years (2028), has been granted. Etanercept or Enbrel is a biopharmaceutical that has been designed to treat autoimmune diseases by interfering with Tumor necrosis factor. It is a TNF inhibitor which is made in living cell cultures rather than in a chemistry lab. It was one of the first successful products to emerge from the flourishing of innovations in cell biology since the 1990s. Structurlly, Enbrel (etanercept) is a dimeric fusion protein consisting of the extracellular ligand binding portion of the human 75 Kilo Dalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human immunoglobulin (IgG1). Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids and has an apparent molecular weight of approximately 150 Kilo Daltons. Enbrel Biosimilars Clinical Insight by Company
For more information about this report visit http://www.researchandmarkets.com/research/778txw/enbrel
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024006314/en/ |
